Patent · US Active

Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties

US11542337B2 · kind B2 · utility

0Cited by

0References

12Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Zhiqiang Chen · Beijing, CN
Yueming Qian · Pepperell, US
Xuankuo Xu · Boxborough, US
Chao Huang · Taichung, TW
Zhijun Tan · Acton, US
Zhengjian Li · Sudbury, US

Key dates

Filing date	Dec 22, 2017
Grant date	Jan 3, 2023
Priority date	—
Expiry date	Jan 9, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

In certain embodiments, the disclosure provides an IgG4 antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises: (a) a modified IgG4 CH1 region having a substitution of the lysine residue at position 196; or (b) a modified IgG4 hinge region having a substitution of the serine residue at position 217, the glycine residue at position 220, the proline residue at position 224 or the proline residue at position 225. Preferably, the IgG4 antibody further comprises a substitution of the serine residue at position 228 in the heavy chain hinge region.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.